John West - Personalis CEO, CoFounder
| PSNL Stock | USD 3.60 0.13 3.75% |
Insider
John West is CEO, CoFounder of Personalis
| Age | 67 |
| Address | 6600 Dumbarton Circle, Fremont, CA, United States, 94555 |
| Phone | 650 752 1300 |
| Web | https://www.personalis.com |
John West Latest Insider Activity
Tracking and analyzing the buying and selling activities of John West against Personalis stock is an integral part of due diligence when investing in Personalis. John West insider activity provides valuable insight into whether Personalis is net buyers or sellers over its current business cycle. Note, Personalis insiders must abide by specific rules, including filing SEC forms every time they buy or sell Personalis'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John West over six months ago Acquisition by John West of 450000 shares of Personalis subject to Rule 16b-3 |
Personalis Management Efficiency
The company has return on total asset (ROA) of (0.1878) % which means that it has lost $0.1878 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5752) %, meaning that it created substantial loss on money invested by shareholders. Personalis' management efficiency ratios could be used to measure how well Personalis manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.51. Return On Capital Employed is expected to rise to -0.59 this year. At this time, Personalis' Net Tangible Assets are quite stable compared to the past year. Non Currrent Assets Other is expected to rise to about 6.5 M this year, although the value of Non Current Assets Total will most likely fall to about 49.5 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Flavia Pease | Charles River Laboratories | 51 | |
| Zhihong Zhang | Burning Rock Biotech | 48 | |
| Kevin Haas | Myriad Genetics | 38 | |
| Andy Ament | Guardant Health | N/A | |
| Darya Chudova | Guardant Health | 50 | |
| Camilla Zuckero | Castle Biosciences | N/A | |
| Jonathan MEng | Natera Inc | 51 | |
| Jinxiang Li | Burning Rock Biotech | 39 | |
| Nadia Altomare | Sera Prognostics | 53 | |
| Nicole Lambert | Myriad Genetics | 50 | |
| Aaron Sato | Twist Bioscience Corp | N/A | |
| Abraham Esq | Caredx Inc | 51 | |
| LLM LLM | Natera Inc | 55 | |
| Yusheng Han | Burning Rock Biotech | 45 | |
| Dov Oppenheim | DarioHealth Corp | N/A | |
| Michael MBA | Natera Inc | 44 | |
| Zvi David | DarioHealth Corp | 63 | |
| Robert Harrison | Sera Prognostics | 58 | |
| Paul Kearney | Sera Prognostics | 56 | |
| Scott Ericksen | Illumina | 51 | |
| RN RN | Castle Biosciences | 56 | |
Management Performance
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.19 |
Personalis Leadership Team
Elected by the shareholders, the Personalis' board of directors comprises two types of representatives: Personalis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Personalis. The board's role is to monitor Personalis' management team and ensure that shareholders' interests are well served. Personalis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Personalis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Hall, CEO President | ||
| Stephen JD, Senior Officer | ||
| Christian Haudenschild, Senior Operations | ||
| DPHIL FRCP, CoFounder Board | ||
| Carol Tillis, VP Admin | ||
| MS MD, Executive Officer | ||
| MD MS, VP Officer | ||
| Aaron Tachibana, CFO COO | ||
| John West, CEO, CoFounder | ||
| Michael Fitzpatrick, Vice Sales | ||
| Atul Butte, CoFounder Board | ||
| Deepshikha Bhandari, Quality Regulatory | ||
| Stephane Mouradian, Senior Development | ||
| Michael Snyder, CoFounder Board |
Personalis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Personalis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (1.05) % | ||||
| Operating Margin | (0.56) % | ||||
| Current Valuation | 146.65 M | ||||
| Shares Outstanding | 70.65 M | ||||
| Shares Owned By Insiders | 19.29 % | ||||
| Shares Owned By Institutions | 53.10 % | ||||
| Number Of Shares Shorted | 3.24 M | ||||
| Price To Book | 1.47 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Personalis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Personalis Stock please use our How to buy in Personalis Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Personalis. If investors know Personalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Personalis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.73) | Revenue Per Share 1.637 | Quarterly Revenue Growth 0.409 | Return On Assets (0.19) | Return On Equity (0.58) |
The market value of Personalis is measured differently than its book value, which is the value of Personalis that is recorded on the company's balance sheet. Investors also form their own opinion of Personalis' value that differs from its market value or its book value, called intrinsic value, which is Personalis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Personalis' market value can be influenced by many factors that don't directly affect Personalis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Personalis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Personalis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Personalis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.